Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP3 | Q9H4L4 | 2/20 | 0.36 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.36 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.36 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.36 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | CASP6 | P55212 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | RAD1 | O60671 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Disufenton SCHEMBL13916412 | 1.00 | SENP3 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| Disufenton SCHEMBL727315 | 1.00 | SENP3 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| Disufenton SCHEMBL1922127 | 0.98 | SENP3 (0.35) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL13488468 | 0.91 | SMN1; SMN2 (0.38) | ENPP2ALDH1A1RAD1P2RY6LMNA | |
| SCHEMBL5553705 | 0.85 | SENP3 (0.33) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL5549780 | 0.85 | SENP3 (0.33) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL20848694 | 0.84 | TDP1 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL10293546 | 0.84 | SENP3 (0.37) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL6449477 | 0.83 | KMT2A (0.38) | ALDH1A1HSD17B10CYP2C9CYP2C19TDP1 | |
| SCHEMBL15216504 | 0.81 | KMT2A (0.38) | ALDH1A1HSD17B10CYP2C9CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | Karuna Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025055893-A1 | PHARMACEUTICAL DOSAGE FORMS AND PREPARATION METHODS THEREOF | Triastek, Inc. (CN) | 2025-03-20 | — | — | WO | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3642202-B1 | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-110944998-B | Dihydro-pyrrolo-pyridine derivatives | 辉瑞大药厂 | 2022-08-16 | — | — | CN | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022077034-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | NAPA THERAPEUTICS LTD. (VG) | 2022-04-14 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | SENP3 4450/4885SENP2 4464/4885SENP1 4044/4885 |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SENP3 2474/4885SENP2 2602/4885SENP1 3478/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SENP3 2474/4885SENP2 2602/4885SENP1 3478/4885 |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | SENP3 2839/4885SENP2 3371/4885SENP1 3711/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | SENP3 2839/4885SENP2 3371/4885SENP1 3711/4885 |
| US-11524954-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | SENP3 4450/4885SENP2 4464/4885SENP1 4044/4885 |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | CHRM3, CHRM4, CHRM2 | SENP3 3960/4885SENP2 4646/4885SENP1 4746/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | SENP3 3661/4885SENP2 4490/4885SENP1 3954/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | SENP3 4383/4885SENP2 4765/4885SENP1 4562/4885 |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | SENP3 2839/4885SENP2 3371/4885SENP1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.